Semaglutide Weight Loss Results: What to Really Expect in 2025
Medically Reviewed
Dr. Sean Arora
MD, board-certified physician
Arora Health (Trimi clinician network)
Last reviewed: November 26, 2025
The Clinical Trial Data: What the Studies Show
What did the STEP 1 trial measure?
STEP 1 studied once-weekly injected semaglutide alongside lifestyle intervention in adults with overweight or obesity who did not have diabetes. Mean body-weight reduction in the semaglutide group was 14.9% at 68 weeks. This result describes the studied regimen and population.
Source: Wilding et al., NEJM, 2021.
Does that predict my results with Trimi?
No. STEP 1 did not measure outcomes for Trimi or for Trimi's compounded preparations. A trial-group average does not predict an individual's result. Discuss treatment options, risks and expectations with a licensed provider. Compounded medications are not FDA-approved.
Start Your Semaglutide Journey
Get Started TodayRelated Articles
Related Articles
Semaglutide Dosage Guide
Detailed information on starting doses, titration schedules, and maintenance dosing for semaglutide.
Read moreSemaglutide Side Effects
Understanding common and rare side effects of semaglutide and effective management strategies.
Read moreSemaglutide Clinical Results
Analysis of STEP trial data and real-world clinical evidence for semaglutide efficacy.
Read moreSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.